Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

Paul G. Richardson,Shaji Kumar,Tamas Masszi,Norbert Grzasko,Nizar J. Bahlis,Markus Hansson,Luděk Pour,Irwindeep Sandhu,Peter Ganly,Bartrum W. Baker,Sharon Jackson,Anne-Marie Stoppa,Peter Gimsing,Laurent Garderet,Cyrille Touzeau,Francis K. Buadi,Jacob P. Laubach,Michele Cavo,Mohamed Darif,Richard Labotka,Deborah Berg,Philippe Moreau

Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

2021

PURPOSEThe double-blind, placebo-controlled, phase III TOURMALINE-MM1 study demonstrated a statistically significant improvement in progression-free survival with ixazomib-lenalidomide-dexamethason...

Keywords:

Lenalidomide
Internal medicine
Medicine
overall survival
Oncology
in patient
Dexamethasone
Ixazomib
Refractory Multiple Myeloma
Text mining

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations